Raia Drogasil SA Stock Sao Paulo
Stocks
DROG3
BRDROGACNOR1
Drug Retailers
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - BRL | - |
|
| 08-05 | Raia Drogasil S.A., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 08-04 | Raia Drogasil S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 33.89B 6.64B 5.75B 5.37B 4.91B 9.26B 633B 9.4B 63.02B 24.73B 317B 24.94B 24.39B 1,055B | P/E 2026 * |
22.3x | P/E 2027 * | 16.9x |
|---|---|---|---|---|---|
| Enterprise Value | 42.17B 8.26B 7.15B 6.69B 6.11B 11.52B 788B 11.7B 78.42B 30.77B 394B 31.03B 30.36B 1,313B | EV / Sales 2026 * |
0.93x | EV / Sales 2027 * | 0.82x |
| Free-Float |
73.24% | Yield 2026 * |
1.87% | Yield 2027 * | 2.23% |
Last Transcript: Raia Drogasil SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2024-12-31 | |
| Director of Finance/CFO | 63 | 2013-04-28 | |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 50 | 2024-12-31 | |
| Director/Board Member | - | - | |
Gilberto Lerio
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.91% | +3.02% | -3.00% | +17.47% | 1.32B | |
| +15.52% | +16.30% | +12.83% | +26.85% | 499M | |
| +0.53% | +0.42% | -10.48% | +32.70% | 68.15M | |
| Average | +5.65% | +9.56% | -0.22% | +25.67% | 628.72M | |
| Weighted average by Cap. | +4.76% | +10.09% | +0.91% | +20.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45.23B 8.86B 7.67B 7.17B 6.56B 12.35B 845B 12.55B 84.12B 33.01B 423B 33.29B 32.56B 1,409B | 52.24B 10.24B 8.86B 8.28B 7.57B 14.27B 976B 14.49B 97.14B 38.12B 488B 38.44B 37.6B 1,627B |
| Net income | 1.5B 294M 254M 238M 217M 409M 28.02B 416M 2.79B 1.09B 14.02B 1.1B 1.08B 46.69B | 2.04B 400M 346M 324M 296M 557M 38.14B 566M 3.79B 1.49B 19.08B 1.5B 1.47B 63.55B |
| Net Debt | 8.28B 1.62B 1.41B 1.31B 1.2B 2.26B 155B 2.3B 15.4B 6.04B 77.45B 6.1B 5.96B 258B | 8.97B 1.76B 1.52B 1.42B 1.3B 2.45B 168B 2.49B 16.69B 6.55B 83.91B 6.6B 6.46B 279B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RADL3 Stock
- DROG3 Stock
Select your edition
All financial news and data tailored to specific country editions
